Issue Archive
August 2021 | Volume 20 | Issue 8
Editorials
Nivolumab Induced Psoriasis Successfully Treated With Acitretin
Immunotherapy is emerging as a promising alternative treatment for a variety of solid tumors. Its beneficial effects are mediated through hijacking the immune system to mount an anti-tumor response. O...
Read MoreImmunohistochemistry Utilization in Medicare Beneficiaries by Mohs Surgeons From 2012-2017
Based on surveys by Robinson1 in 2001 and Trimble and Cherpeli2 in 2013, Immunohistochemistry (IHC) utilization in Mohs micrographic surgery (MMS) has been rising. Although these surveys pro...
Read MoreEfficacy of Topical Herbal Anti-inflammatory Treatment (HAT1) for Treating Psoriasis: An Investigator-Initiated Open Label Study
Atopical botanical complex from a novel combination of phytochemicals, denoted as herbal anti-inflammatory treatment 1 (HAT1), was developed for topical treatment of psoriasis....
Read MoreHair Care Professionals as Community Health Partners in Detection and Management of Alopecia: A Pilot Survey Study
Background: Alopecia is one of the most common diagnoses encountered by dermatologists; despite this, patients with hair loss often seek help from hair stylists prior to seeing a physician.
Obje...
Read MoreCOVID-19 in Individuals Treated With Long-Term Hydroxychloroquine: A Propensity Score-Matched Analysis of Cicatricial Alopecia Patients
Early in the COVID-19 pandemic, anti-malarial agent hydroxychloroquine (HCQ) was touted as a potentially effective COVID-19 treatment due to its purported antiinflammatory and antiviral effects....
Read More
Original Articles
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2
Background: Anti-interleukin (IL)-17 biologic agents used to treat psoriasis are associated with onset/exacerbation of inflammatory bowel disease (IBD). Objectives: To determine the incidence of IBD o...
Read MoreUpdate on Facial Erythema in Rosacea
Dermatologists are cognizant of the multiple clinical manifestations of rosacea, particularly persistent facial erythema, which has been deemed to be the most prevalent diagnostic feature and often po...
Read MoreCharacteristics of Superficial Basal Cell Carcinomas Containing More Aggressive Subtypes on Final Histopathologic Diagnosis
Background: The prognosis and treatment of basal cell carcinoma (BCC) are largely dependent on tumor subtype, which is typically determined by punch or shave biopsy. Data regarding concordance between...
Read MoreCalcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials
Background: Psoriasis vulgaris is not easy to manage, even when mild. Knowledge of the efficacy of most topical therapies in this population is limited.
Objective: To assess the efficacy of calc...
Read MoreReview of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis
Psoriasis is a chronic inflammatory skin condition resulting from the dysregulation of cytokines. Apremilast, an oral phosphodiesterase-4 inhibitor is approved by the Federal Drug Administration (FDA)...
Read MoreProceedings Report of the Fifth Symposium on Hidradenitis Suppurativa Advances (SHSA) 2020
The Symposium on Hidradenitis Suppurativa Advances (SHSA) is a joint meeting of the United States Hidradenitis Suppurativa Foundation (HSF) and the Canadian Hidradenitis Suppurativa Foundation (CHSF)....
Read MoreAdvances and Considerations in the Management of Actinic Keratosis: An Expert Consensus Panel Report
Background: Actinic Keratosis (AK) is a potentially pre-malignant tumor with a poorly defined risk of progression to invasive squamous cell carcinoma (SCC). Because of the typical need for recurrent c...
Read MoreClinical Evidence of Cell-Targeted Topical Therapy for Treating Skin Dyspigmentation
Background: New development of cell-targeted therapies to enable site-specific skin tissue drug delivery may reduce off-target effects, decrease unwanted toxicities, and enhance drug efficacy. These e...
Read MoreAntihistamines in Psoriasis
Psoriasis is polygenic, interleukin (IL)-17 and IL-23 driven chronic relapsing inflammatory multisystem disease caused by a complex interplay of endogenous and environmental factors. The most common a...
Read MoreFixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%–5% Affected Body Surface Area
Introduction: Patients with psoriasis and low body surface area (BSA) involvement often experience substantially reduced quality of life and may be candidates for topical therapies. Fixed-combination ...
Read MoreSustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)
Background: Long-term efficacy, safety, and quality of life with ixekizumab (IXE) through 5 years in UNCOVER-1 and UNCOVER-2 patients with baseline scalp, nail, or palmoplantar psoriasis were assessed...
Read More
Case Reports
Combining Panitumumab With Anti-PD-1 Antibody in Cutaneous Squamous Cell Carcinoma of the Head and Neck After Inadequate Response to Anti-PD-1 Antibody Alone
Anti-epidermal growth factor receptor (EGFR) antibodies and anti-programmed cell death 1 protein (PD-1) antibodies have been used separately to treat metastatic cutaneous squamous cell carcinoma (cSCC...
Read MoreHerpes Zoster Following COVID-19 Vaccination
Vaccination is an important intervention in preventing the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Messenger RNA (mRNA) vaccines from Pfizer™ and Moderna™ a...
Read MoreAn Extensive Presentation of Cutaneous Angiosarcoma
In this report, the case of a 58-year-old male with extensive, rapidly growing cutaneous angiosarcoma is described. Though involvement of the scalp is common in cutaneous angiosarcoma, the extent of c...
Read More
